Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescence analysis of Phospho-Aurora A pThr288 was done on 70% confluent log phase HeLa cells treated with 3uM Nocodazole for 24hrs. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with Phospho-Aurora A pThr288 Rabbit Polyclonal Antibody ( 441210G) at 2ug/ml in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjugate (Product # A27034) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d is a merged image showing spindle localization. Panel e is untreated cell with no signal. Panel f is a no primary antibody control. The images were captured at 60X magnification.
|Tested species reactivity||Mouse, Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||The antiserum was produced against a chemically synthesized phosphopeptide derived from the region of human Aurora A Kinase that contains threonine 288. The sequence is highly conserved in mouse and rat.|
|Purification||Antigen affinity chromatography|
|Storage buffer||Dulbecco's PBS, pH 7.3, with 50% glycerol, 1mg/ml BSA|
|Contains||0.05% sodium azide|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
|Western Blot (WB)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Aurora A plays a role in cell cycle regulation during anaphase and/or telophase, in relation to the function of the centrosome/spindle pole region during chromosome segregation. Aurora A plays a key role during tumor development and progression and is overexpressed in many human cancers including breast, ovarian and colorectal. Aurora A is viewed as a potential target for anticancer drug treatment.Tissue specificity: Highly expressed in testis and weakly in skeletal muscle, thymus and spleen. Also highly expressed in colon, ovarian, prostate, neuroblastoma, breast and cervical cancer cell lines.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
AIK; ARK-1; ARK1; Aurora 2; aurora A; Aurora family kinase 1; Aurora kinase A; Aurora-A; Aurora-family kinase 1; aurora-related kinase 1; aurora/IPL1-like kinase; Aurora/IPL1-related kinase 1; AYK1; Breast tumor-amplified kinase; Breast-tumor-amplified kinase; BTAK; EC 184.108.40.206; IAK1; Ipl1- and aurora-related kinase 1; protein phosphatase 1, regulatory subunit 47; Serine/threonine; Serine/threonine kinase 15; serine/threonine kinase 6; serine/threonine protein kinase 15; Serine/threonine-protein kinase 15; Serine/threonine-protein kinase 6; Serine/threonine-protein kinase aurora-A; Serine/threonine-protein kinase Ayk1; STK15; STK6
AIK; Airk; AIRK1; ARK-1; ARK1; AU019385; AURA; AURKA; Aurora-A; AW539821; AYK1; BTAK; IAK; IAK1; PPP1R47; STK15; STK6; STK7